Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Inventory (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Inventory for 13 consecutive years, with $20.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Inventory rose 122.19% to $20.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $20.4 million, a 122.19% increase, with the full-year FY2025 number at $20.4 million, up 122.19% from a year prior.
  • Inventory was $20.4 million for Q4 2025 at Niagen Bioscience, up from $18.8 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $20.4 million in Q4 2025 to a low of $9.2 million in Q4 2024.
  • A 5-year average of $13.7 million and a median of $12.7 million in 2021 define the central range for Inventory.
  • Peak YoY movement for Inventory: tumbled 36.72% in 2024, then soared 122.19% in 2025.
  • Niagen Bioscience's Inventory stood at $13.6 million in 2021, then grew by 7.91% to $14.7 million in 2022, then fell by 1.04% to $14.5 million in 2023, then crashed by 36.72% to $9.2 million in 2024, then soared by 122.19% to $20.4 million in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Inventory are $20.4 million (Q4 2025), $18.8 million (Q3 2025), and $14.4 million (Q2 2025).